NY-PYRAMID-ANALYTICS
11.5.2022 09:02:10 CEST | Business Wire | Press release
GARTNER DATA & ANALYTICS SUMMIT: Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider – next-generation business analytics for the enterprise – has been ranked first for the Augmented Analytics Use Case in the 2022 Gartner Critical Capabilities for Analytics and Business Intelligence Platforms1 . Pyramid scored among the top 5 vendors across all four use cases: Augmented Analytics; Enterprise Analytics; General Analytics; Visual Self-Service Analytics. Twenty (20) companies were evaluated on 12 Critical Capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220511005215/en/
Key Points:
- Pyramid was ranked first among 20 companies for the Augmented Analytics Use Case.
- According to Gartner, “Augmented analytics is the use of enabling technologies such as machine learning and AI to assist with data preparation, insight generation and insight explanation to augment how people explore and analyze data in analytics and BI platforms.”2
- Pyramid has been evaluated in five (5) Gartner Critical Capabilities for Analytics and Business Intelligence Platforms reports.
- Download the 2022 Gartner Critical Capabilities for Analytics and Business Intelligence Platforms.
- Click here to schedule a demo of the Pyramid Decision Intelligence Platform .
“In 2021 Pyramid doubled down on its direct query architecture, increasing the performance of PYRANA, its direct query engine, for both SQL and MDX queries. Pyramid also added new augmentation capabilities and upgraded existing ones across the platform - touching all aspects from data preparation to discovery, through to automated analysis and insights. This year, Pyramid also added 15 new refinements to its smart tools including a new auto-discovery framework to drive explanations, key driver analysis and influencer logic.”3
What is a Gartner Critical Capabilities Report? (Source: Gartner )
A Critical Capabilities document is a comparative analysis that scores competing products or services against a set of critical differentiators identified by Gartner. It shows you which products or services are a best fit in various use cases to provide you actionable advice on which products/services you should add to your vendor shortlists for further evaluation.
As an essential companion to the Gartner Magic Quadrant, this methodology provides deeper insight into providers’ product and service offerings by extending the Magic Quadrant analysis. Use this research to further investigate product and service ratings based on key capabilities set to important, differentiating use cases.
Complete, Unified Decision Intelligence
The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.
The Pyramid Decision Intelligence Platform is rated 4.5 Stars on a scale 1 to 5 and based on 116 reviews on Gartner Peer Insights . Peer Insights™ is Gartner ’s peer-driven ratings and reviews platform for enterprise IT solutions and services covering over 300+ technology markets and 3,000 vendors (Source: Gartner Peer Insights ) .
Quotes
Omri Kohl, Chief Executive Officer and Co-Founder, Pyramid Analytics : “In 2017, and again in 2019, Gartner stated that ‘Augmented Analytics Is the Future of Data and Analytics’3 . We think that future has arrived. The Pyramid Decision Intelligence Platform leverages machine learning and AI techniques to transform how analytics content is developed, consumed, and shared. The Pyramid Platform provides instant access to any data, meets any analytics need, and customizes analytic experiences for any person who would benefit from access to the powerful combination of data and analytics to make intelligent decisions. And that’s everyone.”
1
Gartner, Gartner Critical Capabilities for Analytics and Business Intelligence Platforms, Kurt Schlegel, Rita Sallam, Austin Kronz, Julian Sun, David Pidsley, Anirudh Ganeshan, Georgia O'Callaghan, Kevin Quinn, Shaurya Rana, Christopher Long, 3rd
May 2022
2
Gartner IT Glossary, Augmented Analytics
, as on 10th
May 2022.
3
Gartner, Augmented Analytics Is the Future of Analytics, Rita Sallam, Carlie Idoine, 30 October 2019
Gartner Disclaimer:
Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
GARTNER is a registered trademark and service mark, and PEER INSIGHTS is a trademark and service mark, of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.
About Pyramid Analytics
Pyramid is a pioneering decision intelligence platform provider. Decision Intelligence is what’s next in analytics. The Pyramid Decision Intelligence Platform delivers insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics. More than 1 million decision makers rely on Pyramid to make faster, more intelligent decisions. Schedule a demo .
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital and Viola Growth. Learn more at Pyramid Analytics .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220511005215/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
